Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Core Viewpoint - Sanofi's rilzabrutinib has received orphan drug designation in Japan for the treatment of IgG4-related disease, addressing a significant unmet medical need in a rare and progressive condition [1][7]. Group 1: Rilzabrutinib's Designation and Clinical Evaluation - The Ministry of Health, Labour and Welfare in Japan granted orphan drug designation to rilzabrutinib for IgG4-RD, highlighting the limited treatment options available for this condition [1]. - Rilzabrutinib was evaluated in a phase 2 study, showing a reduction in disease flares and other markers over 52 weeks, while minimizing the need for glucocorticoids [2]. - The safety profile of rilzabrutinib in the phase 2 study was consistent with previous studies, with common adverse events including diarrhea, COVID-19, dizziness, dry mouth, and nausea [2]. Group 2: Broader Applications and Regulatory Status - Rilzabrutinib is being studied for multiple rare immune-mediated diseases and has received approval for immune thrombocytopenia (ITP) in the US, EU, and UAE, with ongoing regulatory review in Japan [3]. - The drug has received expedited designations from global regulatory authorities for various conditions, including IgG4-RD and sickle cell disease, although these uses remain investigational [3]. Group 3: Mechanism and Potential Impact - Rilzabrutinib is a novel, oral, reversible covalent BTK inhibitor that aims to restore immune balance through multi-immune modulation, targeting critical pathways in immune-mediated diseases [4]. - The drug's mechanism involves selective inhibition of BTK, which is crucial in various immune-mediated disease processes [4]. Group 4: Understanding IgG4-RD - IgG4-RD is a chronic, relapsing, immune-mediated rare disease that can affect multiple organs, leading to serious damage and potentially fatal outcomes [5]. - The global prevalence of IgG4-RD remains unknown due to its rarity and diagnostic challenges [5]. Group 5: Company Overview - Sanofi is an R&D driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [6].